In addition to hematological malignancies where Mcl-1 is the major target, Myc-driven diseases such as neuroblastoma are a trending area for the development of CDK9 inhibitors [28, 59], with a few compounds being actively tested in the clinic. This evidence concerns the gene MYC and neuroblastoma.